STAT3 in Cancer—Friend or Foe?
Author:
Publisher
MDPI AG
Subject
Cancer Research,Oncology
Link
http://www.mdpi.com/2072-6694/6/3/1408/pdf
Reference182 articles.
1. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
2. The STATs of cancer — new molecular targets come of age
3. Targeting STAT3 in cancer: how successful are we?
4. Stat1 and STAT3 in Tumorigenesis: Two Sides of the Same Coin?;Pensa,2009
5. How should we define STAT3 as an oncogene and as a potential target for therapy?
Cited by 98 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Evaluating the specific STAT3 inhibitor YHO-1701 in ovarian cancer cell lines and patient-derived cell models: efficacy, mechanisms, and therapeutic potential;Journal of Gynecologic Oncology;2025
2. Research progress of multi-target HDAC inhibitors blocking the BRD4-LIFR-JAK1-STAT3 signaling pathway in the treatment of cancer;Bioorganic & Medicinal Chemistry;2024-08
3. Preclinical development and clinical studies of targeted JAK/STAT combined Anti-PD-1/PD-L1 therapy;International Immunopharmacology;2024-03
4. Cell-autonomous GP130 activation suppresses prostate cancer development via STAT3/ARF/p53-driven senescence and confers an immune-active tumor microenvironment;2024-02-12
5. Fibronectin Type III Domain Containing 3B as a Potential Prognostic and Therapeutic Biomarker for Glioblastoma;Biomedicines;2023-11-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3